Research
Hormonal
Activation of central melanocortin receptors increases sympathetic nerve activity to white adipose tissue, leading to lipid mobilization and reduced fat storage.
Your brain uses your nervous system to tell your fat cells whether to store or burn fat. Activating certain brain receptors can signal your body to release stored fat, independent of how much you eat.
GoodSupportsHIGH confidence
i.c.v. administration of MTII increased sympathetic nerve activity (SNA) in WAT, with a 68% ± 20% increase 6 hours after a dose of 5 nmol... Chronic i.c.v. MTII infusion also increased mRNA expression of adipose TAG lipase (ATGL), which was recently identified as an important triacylglycerol hydrolase promoting the catabolism of stored fat
Why this rating
Strong mechanistic evidence in rodents.
Source
The central melanocortin system directly controls peripheral lipid metabolism
Rubén Nogueiras et al. · Journal of Clinical Investigation · 2007
DOI 10.1172/jci31743
mechanism_onlyCited 389×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Pharmacological blockade of central melanocortin receptors (CNS-Mcr) directly promotes lipid uptake, triglyceride synthesis, and fat accumulation in white adipose tissue (WAT) independent of food intake.Good
- Blockade of central melanocortin receptors decreases glucose utilization in skeletal muscle and brown adipose tissue while increasing glucose uptake in white adipose tissue.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →